ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

ProKidney Corp. (Nasdaq: PROK), a leading late clinical-stage biotech company focused on developing a first-in-class cell therapy for chronic kidney disease (CKD), has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place in New York, NY from September 4-6, 2024.

Key details:

• Date: Thursday, September 5, 2024
• Time: 7:00 a.m. ET
• Format: Fireside Chat

A live webcast will be available through the company's website, with a 90-day replay option after the event. ProKidney's management team will also host one-on-one meetings with interested investors during the conference.

News Market Reaction – PROK

-7.53%

1 alert

-7.53% News Effect

On the day this news was published, PROK declined 7.53%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22^nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.

Morgan Stanley 22nd Annual Global Healthcare Conference
Date:	Thursday, September 5, 2024
Time:	7:00 a.m. ET
Format:	Fireside Chat
Webcast Link:	https://cc.webcasts.com/morg007/090424a_js/?entity=120_8TXT47O

The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the fireside chat, a replay of the webcast will be available for 90 days.

The ProKidney management team will also host one-on-one meetings during this event. Interested investors should contact their Morgan Stanley representative to schedule meetings.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT^®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in patients with diabetes and advanced CKD. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.

Investor Contacts:

ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com

LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com

FAQ

When is ProKidney (PROK) participating in the Morgan Stanley Healthcare Conference?

ProKidney (PROK) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 7:00 a.m. ET.

What type of presentation will ProKidney (PROK) give at the Morgan Stanley conference?

ProKidney (PROK) will participate in a fireside chat format presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference.

Where can investors access the webcast of ProKidney's (PROK) presentation?

Investors can access the live webcast through the 'Events' section of the Investor Relations tab on ProKidney's website at www.prokidney.com.

How long will the replay of ProKidney's (PROK) presentation be available?

The replay of ProKidney's (PROK) presentation will be available for 90 days following the completion of the fireside chat.

What is ProKidney's (PROK) main focus in biotechnology?

ProKidney (PROK) is focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD).